

# Bradley C Leibovich

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7201947/publications.pdf>

Version: 2024-02-01

161  
papers

6,717  
citations

61984

43  
h-index

74163

75  
g-index

163  
all docs

163  
docs citations

163  
times ranked

6758  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. <i>BJU International</i> , 2004, 94, 33-41.	2.5	517
2	PROSTATE CANCER DIAGNOSIS USING A SATURATION NEEDLE BIOPSY TECHNIQUE AFTER PREVIOUS NEGATIVE SEXTANT BIOPSIES. <i>Journal of Urology</i> , 2001, 166, 86-92.	0.4	366
3	Survival after complete surgical resection of multiple metastases from renal cell carcinoma. <i>Cancer</i> , 2011, 117, 2873-2882.	4.1	344
4	Histological Subtype is an Independent Predictor of Outcome for Patients With Renal Cell Carcinoma. <i>Journal of Urology</i> , 2010, 183, 1309-1316.	0.4	339
5	A SCORING ALGORITHM TO PREDICT SURVIVAL FOR PATIENTS WITH METASTATIC CLEAR CELL RENAL CELL CARCINOMA: A STRATIFICATION TOOL FOR PROSPECTIVE CLINICAL TRIALS. <i>Journal of Urology</i> , 2005, 174, 1759-1763.	0.4	201
6	Mayo Adhesive Probability Score: An Accurate Image-based Scoring System to Predict Adherent Perinephric Fat in Partial Nephrectomy. <i>European Urology</i> , 2014, 66, 1165-1171.	1.9	190
7	Survival of patients with carcinoma in situ of the urinary bladder. <i>Cancer</i> , 1999, 85, 2469-2474.	4.1	143
8	Predicting the survival of bladder carcinoma patients treated with radical cystectomy. <i>Cancer</i> , 2000, 88, 2326-2332.	4.1	135
9	The High-Dose Aldesleukin "Select" Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 561-568.	7.0	133
10	Predicting Oncologic Outcomes in Renal Cell Carcinoma After Surgery. <i>European Urology</i> , 2018, 73, 772-780.	1.9	131
11	Grading and Staging of Bladder Carcinoma in Transurethral Resection Specimens. <i>American Journal of Clinical Pathology</i> , 2000, 113, 275-279.	0.7	124
12	Expanded Clinical Phenotype, Oncological Associations, and Immunopathologic Insights of Paraneoplastic Kelch-like Protein-11 Encephalitis. <i>JAMA Neurology</i> , 2020, 77, 1420.	9.0	109
13	Management of inferior vena cava tumor thrombus in locally advanced renal cell carcinoma. <i>Therapeutic Advances in Urology</i> , 2015, 7, 216-229.	2.0	106
14	Paraganglioma of the urinary bladder. , 2000, 88, 844-852.		105
15	Decreased Skeletal Muscle Mass is Associated with an Increased Risk of Mortality after Radical Nephrectomy for Localized Renal Cell Cancer. <i>Journal of Urology</i> , 2016, 195, 270-276.	0.4	104
16	Perioperative Outcomes Following Surgical Resection of Renal Cell Carcinoma with Inferior Vena Cava Thrombus Extending Above the Hepatic Veins: A Contemporary Multicenter Experience. <i>European Urology</i> , 2014, 66, 584-592.	1.9	100
17	The Probability of Aggressive Versus Indolent Histology Based on Renal Tumor Size: Implications for Surveillance and Treatment. <i>European Urology</i> , 2018, 74, 489-497.	1.9	93
18	Tumor size predicts the survival of patients with pathologic stage t2 bladder carcinoma. <i>Cancer</i> , 1999, 85, 2638-2647.	4.1	84

#	ARTICLE	IF	CITATIONS
19	Renal Mass Biopsy: Always, Sometimes, or Never?. <i>European Urology</i> , 2016, 70, 403-406.	1.9	80
20	Application of the Stage, Size, Grade, and Necrosis (SSIGN) Score for Clear Cell Renal Cell Carcinoma in Contemporary Patients. <i>European Urology</i> , 2017, 71, 665-673.	1.9	80
21	The role of lymph node dissection in the management of renal cell carcinoma: a systematic review and meta-analysis. <i>BJU International</i> , 2018, 121, 684-698.	2.5	79
22	Oncologic Outcomes Following Surgical Resection of Renal Cell Carcinoma with Inferior Vena Caval Thrombus Extending Above the Hepatic Veins: A Contemporary Multicenter Cohort. <i>Journal of Urology</i> , 2014, 192, 1050-1056.	0.4	76
23	Predicting Renal Function Outcomes After Partial and Radical Nephrectomy. <i>European Urology</i> , 2019, 75, 766-772.	1.9	75
24	Surgical Metastasectomy in Renal Cell Carcinoma: A Systematic Review. <i>European Urology Oncology</i> , 2019, 2, 141-149.	5.4	73
25	Neurofibroma of the urinary bladder. <i>Cancer</i> , 1999, 86, 505-513.	4.1	72
26	Hemangioma of the urinary bladder. , 1999, 86, 498-504.		71
27	TFEB-VEGFA (6p21.1) co-amplified renal cell carcinoma: a distinct entity with potential implications for clinical management. <i>Modern Pathology</i> , 2017, 30, 998-1012.	5.5	70
28	Renal Cell Carcinoma with Isolated Lymph Node Involvement: Long-term Natural History and Predictors of Oncologic Outcomes Following Surgical Resection. <i>European Urology</i> , 2017, 72, 300-306.	1.9	69
29	The adjuvant treatment of kidney cancer: a multidisciplinary outlook. <i>Nature Reviews Nephrology</i> , 2019, 15, 423-433.	9.6	68
30	Clinical and radiographic predictors of the need for inferior vena cava resection during nephrectomy for patients with renal cell carcinoma and caval tumour thrombus. <i>BJU International</i> , 2015, 116, 388-396.	2.5	66
31	Small (< 4 cm) Renal Mass: Differentiation of Oncocytoma From Renal Cell Carcinoma on Biphasic Contrast-Enhanced CT. <i>American Journal of Roentgenology</i> , 2015, 205, 999-1007.	2.2	66
32	Surgical Management, Complications, and Outcome of Radical Nephrectomy with Inferior Vena Cava Tumor Thrombectomy Facilitated by Vascular Bypass. <i>Urology</i> , 2008, 72, 148-152.	1.0	63
33	Small (< 4 cm) Renal Masses: Differentiation of Angiomyolipoma Without Visible Fat From Renal Cell Carcinoma Using Unenhanced and Contrast-Enhanced CT. <i>American Journal of Roentgenology</i> , 2015, 205, 1194-1202.	2.2	59
34	Comparative Survival following Initial Cytoreductive Nephrectomy versus Initial Targeted Therapy for Metastatic Renal Cell Carcinoma. <i>Journal of Urology</i> , 2018, 200, 528-534.	0.4	59
35	The influence of obesity-related factors in the etiology of renal cell carcinoma—A mendelian randomization study. <i>PLoS Medicine</i> , 2019, 16, e1002724.	8.4	59
36	Radical Nephrectomy With or Without Lymph Node Dissection for Nonmetastatic Renal Cell Carcinoma: A Propensity Score-based Analysis. <i>European Urology</i> , 2017, 71, 560-567.	1.9	58

#	ARTICLE	IF	CITATIONS
37	Radical Versus Partial Nephrectomy for cT1 Renal Cell Carcinoma. <i>European Urology</i> , 2018, 74, 825-832.	1.9	57
38	Incidence of succinate dehydrogenase and fumarate hydratase-deficient renal cell carcinoma based on immunohistochemical screening with SDHA/SDHB and FH/2SC. <i>Human Pathology</i> , 2019, 91, 114-122.	2.0	57
39	Squamous papilloma of the urinary tract is unrelated to condyloma acuminata. , 2000, 88, 1679-1686.		56
40	Extranodal Extension in Lymph Node-Positive Prostate Cancer. <i>Modern Pathology</i> , 2000, 13, 113-118.	5.5	56
41	Clear Cell Type A and B Molecular Subtypes in Metastatic Clear Cell Renal Cell Carcinoma: Tumor Heterogeneity and Aggressiveness. <i>European Urology</i> , 2017, 71, 979-985.	1.9	52
42	First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. <i>European Urology</i> , 2018, 74, 309-321.	1.9	51
43	JAK2/PD-L1/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management. <i>Modern Pathology</i> , 2019, 32, 1344-1358.	5.5	49
44	Comprehensive Characterization of the Perioperative Morbidity of Cytoreductive Nephrectomy. <i>European Urology</i> , 2016, 69, 84-91.	1.9	47
45	Preoperative neutrophil-lymphocyte ratio predicts death among patients with localized clear cell renal carcinoma undergoing nephrectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1277-1284.	1.6	46
46	Radical Nephrectomy with or without Lymph Node Dissection for High Risk Nonmetastatic Renal Cell Carcinoma: A Multi-Institutional Analysis. <i>Journal of Urology</i> , 2018, 199, 1143-1148.	0.4	46
47	Outcomes After Cryoablation Versus Partial Nephrectomy for Sporadic Renal Tumors in a Solitary Kidney: A Propensity Score Analysis. <i>European Urology</i> , 2018, 73, 254-259.	1.9	45
48	Prognostic evaluation of perinephric fat, renal sinus fat, and renal vein invasion for patients with pathological stage T3a clear-cell renal cell carcinoma. <i>BJU International</i> , 2019, 123, 270-276.	2.5	44
49	Complete Surgical Metastasectomy of Renal Cell Carcinoma in the Post-Cytokine Era. <i>Journal of Urology</i> , 2020, 203, 275-282.	0.4	44
50	The role of imaging, deliberate practice, structure, and improvisation in approaching surgical perfection. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2017, 154, 1329-1336.	0.8	42
51	Lymph Node Dissection is Not Associated with Improved Survival among Patients Undergoing Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: A Propensity Score Based Analysis. <i>Journal of Urology</i> , 2017, 197, 574-579.	0.4	41
52	p53 Alteration in regional lymph node metastases from prostate carcinoma. , 1999, 85, 2455-2459.		38
53	Wide Variation in Opioid Prescribing After Urological Surgery in Tertiary Care Centers. <i>Mayo Clinic Proceedings</i> , 2019, 94, 262-274.	3.0	37
54	Low-Grade Oncocytic Tumor of Kidney (CK7-Positive, CD117-Negative): Incidence in a single institutional experience with clinicopathological and molecular characteristics. <i>Human Pathology</i> , 2021, 114, 9-18.	2.0	37

#	ARTICLE	IF	CITATIONS
55	The Impact of Targeted Therapy on Management of Metastatic Renal Cell Carcinoma: Trends in Systemic Therapy and Cytoreductive Nephrectomy Utilization. <i>Urology</i> , 2015, 85, 442-451.	1.0	35
56	The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?. <i>Future Oncology</i> , 2019, 15, 1683-1695.	2.4	35
57	Subjective and objective heterogeneity scores for differentiating small renal masses using contrast-enhanced CT. <i>Abdominal Radiology</i> , 2017, 42, 1485-1492.	2.1	34
58	Diabetes Mellitus is Independently Associated with an Increased Risk of Mortality in Patients with Clear Cell Renal Cell Carcinoma. <i>Journal of Urology</i> , 2014, 192, 1620-1627.	0.4	33
59	Intratumoral CD14+ Cells and Circulating CD14+HLA-DRlo/neg Monocytes Correlate with Decreased Survival in Patients with Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 4224-4233.	7.0	33
60	Predictors of a Successful Urology Resident Using Medical Student Application Materials. <i>Urology</i> , 2017, 108, 22-28.	1.0	33
61	Renal fossa recurrence after nephrectomy for renal cell carcinoma: prognostic features and oncological outcomes. <i>BJU International</i> , 2017, 119, 116-127.	2.5	33
62	Temporal Trends and Factors Associated with Systemic Therapy after Cytoreductive Nephrectomy: An Analysis of the National Cancer Database. <i>Journal of Urology</i> , 2015, 193, 1108-1113.	0.4	32
63	Radiographic size of retroperitoneal lymph nodes predicts pathological nodal involvement for patients with renal cell carcinoma: development of a risk prediction model. <i>BJU International</i> , 2016, 118, 742-749.	2.5	32
64	Renal Neoplasia in Tuberous Sclerosis: A Study of 41 Patients. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1470-1489.	3.0	31
65	Systematic Review of the Management of Local Kidney Cancer Relapse. <i>European Urology Oncology</i> , 2018, 1, 512-523.	5.4	30
66	The Temporal Association of Robotic Surgical Diffusion with Overtreatment of the Small Renal Mass. <i>Journal of Urology</i> , 2018, 200, 981-988.	0.4	30
67	Larger Nephron Size and Nephrosclerosis Predict Progressive CKD and Mortality after Radical Nephrectomy for Tumor and Independent of Kidney Function. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2642-2652.	6.1	30
68	Higher Expression of Topoisomerase II Alpha Is an Independent Marker of Increased Risk of Cancer-specific Death in Patients with Clear Cell Renal Cell Carcinoma. <i>European Urology</i> , 2014, 66, 929-935.	1.9	29
69	Leucine Zipper 4 Autoantibody: A Novel Germ Cell Tumor and Paraneoplastic Biomarker. <i>Annals of Neurology</i> , 2021, 89, 1001-1010.	5.3	27
70	BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor. <i>BMC Urology</i> , 2017, 17, 19.	1.4	26
71	Impact of Rhabdoid Differentiation on Prognosis for Patients with Grade 4 Renal Cell Carcinoma. <i>European Urology</i> , 2015, 68, 5-7.	1.9	25
72	Are We Using the Best Tumor Size Cut-points for Renal Cell Carcinoma Staging?. <i>Urology</i> , 2017, 109, 121-126.	1.0	25

#	ARTICLE	IF	CITATIONS
73	Grading Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis. <i>European Urology</i> , 2021, 79, 225-231.	1.9	25
74	The association between metformin use and oncologic outcomes among surgically treated diabetic patients with localized renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 67.e15-67.e23.	1.6	23
75	Differentiation of Benign From Metastatic Adrenal Masses in Patients With Renal Cell Carcinoma on Contrast-Enhanced CT. <i>American Journal of Roentgenology</i> , 2016, 207, 1031-1038.	2.2	23
76	A Higher Foci Density of Interstitial Fibrosis and Tubular Atrophy Predicts Progressive CKD after a Radical Nephrectomy for Tumor. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2623-2633.	6.1	21
77	A Clinical Decision Aid to Support Personalized Treatment Selection for Patients with Clinical T1 Renal Masses: Results from a Multi-institutional Competing-risks Analysis. <i>European Urology</i> , 2022, 81, 576-585.	1.9	21
78	The Estrogen Pathway: Estrogen Receptor- $\alpha$ , Progesterone Receptor, and Estrogen Receptor- $\beta$ Expression in Radical Cystectomy Urothelial Cell Carcinoma Specimens. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 476-484.	1.9	19
79	Paraneoplastic syndromes are associated with adverse prognosis among patients with renal cell carcinoma undergoing nephrectomy. <i>World Journal of Urology</i> , 2016, 34, 1465-1472.	2.2	19
80	Renal functional outcomes in patients undergoing percutaneous cryoablation or partial nephrectomy for a solitary renal mass. <i>BJU International</i> , 2017, 120, 544-549.	2.5	19
81	The Adverse Survival Implications of Bland Thrombus in Renal Cell Carcinoma With Venous Tumor Thrombus. <i>Urology</i> , 2018, 115, 119-124.	1.0	19
82	Predictors of Scholarly Productivity, Pursuit of Fellowship, and Academic Practice Among Urology Residents Using Medical Student Application Materials. <i>Urology</i> , 2018, 120, 49-55.	1.0	19
83	Impact of a 3D printed model on patients' understanding of renal cryoablation: a prospective pilot study. <i>Abdominal Radiology</i> , 2019, 44, 304-309.	2.1	19
84	Assessment of isochromosome 12p and 12p abnormalities in germ cell tumors using fluorescence in situ hybridization, single-nucleotide polymorphism arrays, and next-generation sequencing/mate-pair sequencing. <i>Human Pathology</i> , 2021, 112, 20-34.	2.0	19
85	Percutaneous Image-guided Core Needle Biopsy for Upper Tract Urothelial Carcinoma. <i>Urology</i> , 2020, 135, 95-100.	1.0	18
86	Surgical Management of Renal Cell Carcinoma. <i>Seminars in Oncology</i> , 2006, 33, 552-562.	2.2	17
87	Pre-treatment neutrophil-to-lymphocyte ratio predicts tumor pathology in newly diagnosed renal tumors. <i>World Journal of Urology</i> , 2016, 34, 1693-1699.	2.2	17
88	Complications and Outcomes Associated With Surgical Management of Renal Cell Carcinoma Involving the Liver: A Matched Cohort Study. <i>Urology</i> , 2017, 99, 155-161.	1.0	17
89	Concordance of PD-L1 and PD-L1 (B7H1) in paired primary and metastatic clear cell renal cell carcinoma. <i>Cancer Medicine</i> , 2020, 9, 1152-1160.	2.8	17
90	The association of statin therapy with clinicopathologic outcomes and survival among patients with localized renal cell carcinoma undergoing nephrectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 388.e11-388.e18.	1.6	16

#	ARTICLE	IF	CITATIONS
91	Coffee consumption and risk of renal cell carcinoma. <i>Cancer Causes and Control</i> , 2017, 28, 857-866.	1.8	16
92	Urinary collecting system invasion is associated with poor survival in patients with clear-cell renal cell carcinoma. <i>BJU International</i> , 2017, 119, 585-590.	2.5	15
93	Comprehensive assessment of renal tumour complexity in a large percutaneous cryoablation cohort. <i>BJU International</i> , 2017, 119, 905-912.	2.5	14
94	Symptomatic Venous Thromboembolism is Associated with Inferior Survival among Patients Undergoing Nephrectomy with Inferior Vena Cava Tumor Thrombectomy for Renal Cell Carcinoma. <i>Journal of Urology</i> , 2018, 200, 520-527.	0.4	14
95	Renal Neuroendocrine Neoplasms: A Single-center Experience. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e343-e349.	1.9	14
96	Partial versus radical nephrectomy in clinical T2 renal masses. <i>International Journal of Urology</i> , 2021, 28, 1149-1154.	1.0	14
97	Comparison of prescribing patterns before and after implementation of evidence-based opioid prescribing guidelines for the postoperative urologic surgery patient. <i>American Journal of Surgery</i> , 2020, 220, 499-504.	1.8	13
98	Excellent long-term disease control with modern radiotherapy techniques for stage I testicular seminoma—The Mayo Clinic experience. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 24.e1-24.e6.	1.6	12
99	Three-dimensional Printing for Renal Cancer and Surgical Planning. <i>European Urology Focus</i> , 2016, 2, 574-576.	3.1	12
100	Synchronous nephron-sparing approaches for bilateral renal masses: perioperative and renal functional outcomes. <i>BJU International</i> , 2018, 122, 243-248.	2.5	12
101	Renal Neoplasia in Polycystic Kidney Disease: An Assessment of Tuberous Sclerosis Complex-associated Renal Neoplasia and PKD1/TSC2 Contiguous Gene Deletion Syndrome. <i>European Urology</i> , 2022, 81, 229-233.	1.9	12
102	Perioperative Morbidity of Lymph Node Dissection for Renal Cell Carcinoma: A Propensity Score-based Analysis. <i>European Urology</i> , 2018, 73, 469-475.	1.9	10
103	Secondary renal neoplasia following chemotherapy or radiation in pediatric patients. <i>Human Pathology</i> , 2020, 103, 1-13.	2.0	10
104	Emulating Target Clinical Trials of Radical Nephrectomy With or Without Lymph Node Dissection for Renal Cell Carcinoma. <i>Urology</i> , 2020, 140, 98-106.	1.0	10
105	Concordance of Pathologic Features Between Metastatic Sites and the Primary Tumor in Surgically Resected Metastatic Renal Cell Carcinoma. <i>Urology</i> , 2016, 96, 106-113.	1.0	9
106	Evaluation of beta-blockers and survival among hypertensive patients with renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 36.e1-36.e6.	1.6	9
107	Oncolytic Measles Virotherapy and Opposition to Measles Vaccination. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1834-1839.	3.0	9
108	Safety and Efficacy of Retrograde Pyeloperfusion for Ureteral Protection during Renal Tumor Cryoablation. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 1249-1255.	0.5	9

#	ARTICLE	IF	CITATIONS
109	Severity of Preoperative Proteinuria is a Risk Factor for Overall Mortality in Patients Undergoing Nephrectomy. <i>Journal of Urology</i> , 2017, 198, 795-802.	0.4	8
110	The association of anxiety and depression with perioperative and oncologic outcomes among patients with clear cell renal cell carcinoma undergoing nephrectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 41.e19-41.e27.	1.6	8
111	Association of Partial versus Radical Nephrectomy with Subsequent Hypertension Risk Following Renal Tumor Resection. <i>Journal of Urology</i> , 2019, 202, 69-75.	0.4	8
112	AUA and NCCN surveillance guidelines for RCC: Do they effectively capture recurrences following nephrectomy?. <i>Journal of Clinical Oncology</i> , 2014, 32, 402-402.	1.6	8
113	Clinicopathologic characteristics and survival for adult renal sarcoma: A population-based study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 505.e15-505.e20.	1.6	7
114	Renal neoplasia with papillary architecture involving the pelvicalyceal system. <i>Human Pathology</i> , 2021, 107, 46-57.	2.0	7
115	Simultaneous versus staged partial nephrectomies for bilateral synchronous solid renal masses. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 640.e13-640.e22.	1.6	7
116	Surgical Management and Oncologic Outcomes of Recurrent Venous Tumor Thrombus after Prior Nephrectomy for Renal Cell Carcinoma. <i>European Urology Focus</i> , 2016, 2, 625-630.	3.1	6
117	Assessing the Evidence for the Surgical Management of Renal Cell Carcinoma with Venous Tumor Thrombus: Room to Grow. <i>European Urology</i> , 2016, 70, 281-282.	1.9	6
118	Correlation of Online Physician Reviews and Overall Patient Satisfaction. <i>Mayo Clinic Proceedings</i> , 2018, 93, 404-405.	3.0	6
119	Should Urologists Abandon the Use of Mannitol During Partial Nephrectomy?. <i>European Urology</i> , 2018, 73, 60-61.	1.9	6
120	Risk prediction models for cancer-specific survival following cytoreductive nephrectomy in the contemporary era. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 499.e1-499.e7.	1.6	6
121	Predictors of Urology Resident Surgical Skills, Clinical Communication Skills, Common Sense and In-Service Scores. <i>Urology Practice</i> , 2019, 6, 52-57.	0.5	6
122	A contemporary guide to chromosomal copy number profiling in the diagnosis of renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 512-524.	1.6	6
123	Patient-Reported Outcomes After Percutaneous Renal Ablation: Initial Experience. <i>American Journal of Roentgenology</i> , 2019, 212, 672-676.	2.2	5
124	The natural history of renal cell carcinoma with isolated lymph node metastases following surgical resection from 2006 to 2013. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 932-940.	1.6	5
125	Hypothermia During Partial Nephrectomy for Patients with Renal Tumors: A Randomized Controlled Trial. <i>Journal of Urology</i> , 2021, 205, 1303-1309.	0.4	5
126	The impact of histology on survival for patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy. <i>Indian Journal of Urology</i> , 2014, 30, 38.	0.6	5



#	ARTICLE	IF	CITATIONS
127	Outcomes following cytoreductive nephrectomy without immediate postoperative systemic therapy for patients with synchronous metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 166.e1-166.e8.	1.6	5
128	Long-term Follow-up of a Matched Cohort Study Evaluating the Role of Adjuvant Radiotherapy for Organ-confined Prostate Cancer With a Positive Surgical Margin. <i>Urology</i> , 2017, 109, 145-152.	1.0	4
129	Partial Versus Radical Nephrectomy for the Clinical T1a Renal Mass. <i>European Urology Focus</i> , 2019, 5, 970-972.	3.1	4
130	Renal hypothermia during partial nephrectomy for patients with renal tumours: a randomised controlled clinical trial protocol. <i>BMJ Open</i> , 2019, 9, e025662.	1.9	4
131	Summary from the Kidney Cancer Association's Inaugural Think Thank: Coalition for a Cure. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 167-175.	1.9	4
132	Phase II efficacy trial of pazopanib in non-clear cell metastatic renal cell carcinoma (PINCR trial).. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS4606-TPS4606.	1.6	4
133	Collecting duct carcinoma: A single institution retrospective study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 40, 13.e9-13.e18.	1.6	4
134	Assessment of Risk of Hereditary Predisposition in Patients With Melanoma and/or Mesothelioma and Renal Neoplasia. <i>JAMA Network Open</i> , 2021, 4, e2132615.	5.9	4
135	Percutaneous Cryoablation of Renal Cell Carcinoma with Sinus Vein Involvement Based on Preprocedural Imaging. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 1651-1657.	0.5	3
136	Reply to Patrick O. Richard, Micheal A.S. Jewett and Antonio Finelli's Letter to the Editor re: Alexander Kutikov, Marc C. Smaldone, Robert G. Uzzo, Miki Haifler, Gennady Bratslavsky, Bradley C. Leibovich. Renal Mass Biopsy: Always, Sometimes, or Never? <i>Eur Urol</i> 2016;70:403-406. <i>European Urology</i> , 2017, 71, e47-e48.	1.9	3
137	Re: Robotic versus Open Level I-II Inferior Vena Cava Thrombectomy: A Matched Group Comparative Analysis. <i>Journal of Urology</i> , 2018, 199, 1351-1352.	0.4	3
138	Renal Cell Carcinoma with Inferior Vena Cava Extension: Can Classification Be Optimized to Predict Perioperative Outcomes?. <i>Kidney Cancer</i> , 2020, 4, 111-115.	0.4	3
139	Use of Personalized Printed 3-Dimensional Kidney Models for Simulation before Nephron Sparing Surgery: Methodology and Examples from a Case Series. <i>Urology Practice</i> , 2016, 3, 124-133.	0.5	2
140	Creation of a primary tumor tissue expression biomarker-augmented prognostic model for patients with metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 135.e1-135.e8.	1.6	2
141	Percutaneous resection of metastatic renal cell carcinoma. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2019, 45, 640.	1.5	2
142	Cytogenetics of spermatocytic tumors with a discussion of gain of chromosome 12p in anaplastic variants. <i>Human Pathology</i> , 2022, 124, 85-95.	2.0	2
143	Perioperative Outcomes for Radical Nephrectomy and Level III-IV Inferior Vena Cava Tumor Thrombectomy in Patients with Renal Cell Carcinoma. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2022, 36, 3093-3100.	1.3	2
144	Combination of a fillet flap, free tissue transfer, and autologous tissue grafts in pelvic reconstruction following retroperitoneal sarcoma: A case report. <i>Microsurgery</i> , 2015, 35, 320-323.	1.3	1

#	ARTICLE	IF	CITATIONS
145	Observations on transatlantic renal cell cancer surgery outcomes. <i>BJU International</i> , 2016, 117, 212-214.	2.5	1
146	Frequency and Predictors of Renal Transplantation Among Patients Rendered Surgically Anephric for Sporadic Renal Cancer. <i>Urology</i> , 2019, 126, 134-139.	1.0	1
147	8q24 clear cell renal cell carcinoma germline variant is associated with VHL mutation status and clinical aggressiveness. <i>BMC Urology</i> , 2020, 20, 173.	1.4	1
148	Temporal trends and factors associated with receipt of systemic therapy among patients undergoing cytoreductive nephrectomy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 503-503.	1.6	1
149	Diabetes mellitus and risk of cancer-specific mortality among patients with clear cell renal cell carcinoma undergoing nephrectomy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 516-516.	1.6	1
150	Unplanned Conversion from Partial to Radical Nephrectomy – An Analysis of Incidence, Etiology, and Risk Factors. <i>Journal of Urology</i> , 0, , .	0.4	1
151	Reply by the Authors. <i>Urology</i> , 2018, 115, 190.	1.0	0
152	Inferior vena cava tumour thrombus and renal cell carcinoma. <i>Canadian Journal of Anaesthesia</i> , 2018, 65, 588-589.	1.6	0
153	Survival outcomes for patients with surgically induced end-stage renal disease. <i>Canadian Urological Association Journal</i> , 2019, 14, E65-E73.	0.6	0
154	Reply to Takeshi Takahashi's Letter to the Editor re: Bimal Bhindi, Christine M. Lohse, Phillip J. Schulte, et al. Predicting functional outcomes after partial and radical nephrectomy. <i>Eur Urol</i> 2019;75:766-72. Partial Nephrectomy: –Geocentrism– of the 21st century in the Church of Urology?. <i>European Urology</i> , 2019, 76, e67-e68.	1.9	0
155	Bim Expression in Peritumoral Lymphocytes is Associated with Survival in Patients with Metastatic Clear Cell Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2021, 5, 129-135.	0.4	0
156	Perioperative outcomes following surgical resection of renal cell carcinoma with upper level IVC thrombus: A contemporary multicenter experience.. <i>Journal of Clinical Oncology</i> , 2014, 32, 498-498.	1.6	0
157	Evaluation of post-operative complications and prolonged length of stay following cytoreductive nephrectomy.. <i>Journal of Clinical Oncology</i> , 2015, 33, 420-420.	1.6	0
158	The impact of rhabdoid differentiation on prognosis in patients with grade 4 renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 494-494.	1.6	0
159	Association and prognostic impact of peripheral blood counts with tumor programmed death ligand one expression.. <i>Journal of Clinical Oncology</i> , 2015, 33, 447-447.	1.6	0
160	Prognostic impact of peripheral blood counts in patients with non-metastatic clear cell renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15590-e15590.	1.6	0
161	Reply by Authors. <i>Journal of Urology</i> , 2020, 203, 282-282.	0.4	0